• Vaccine Name: Cancer Her-2/neu Protein Subunit Vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0011363
• Type: Subunit vaccine
• Status: Research
• Antigen: ERBB2
• ERBB2 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant: IL-12 vacince adjuvant
  • Adjuvant name: IL-12 vacince adjuvant
  • VO adjuvant ID: VO_0001147
  • Description: Gerbu Adjuvant and recombinant IL-2 (Wagner et al., 2007).
• Adjuvant: Gerbu vaccine adjuvant
  • Adjuvant name: Gerbu vaccine adjuvant
  • VO adjuvant ID: VO_0001293
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: FVB/N, BALB/c
• Vaccination Protocol: FVB/N transgenic mice spontaneously developing c-neu overexpressing breast cancers were used. Mice were immunized with the combination of the three peptides P4, P6, and P7 coupled to tetanus toxoid (TT-conjugates; BALB/c and FVB/N n = 5/group, MMTV-c-neu trangenic mice n = 8/group) using 15 μg of each peptide conjugate or with co-applicated IL-12 (BALB/c and FVB/N n = 5/group, MMTV-c-neu trangenic mice n = 7/group). Control BALB/c and FVB/N mice (n = 5/group) received TT and control MMTV-c-neu transgenic mice received TT (n = 8) or IL-12 (n = 5) alone or remained unimmunized (n = 8) (Wagner et al., 2007).
• Efficacy: At the time all untreated mice had developed tumors about 40% of peptide-immunized mice and nearly 60% of mice immunized with the peptide vaccine co-applied with IL-12 remained tumor free (Wagner et al., 2007).